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Introduction
============

The neural retina represents an attractive model for investigating the molecular basis of progenitor cell proliferation and cell fate diversification in the central nervous system (CNS). The advantages of the retinal model system arise from the capacity for in vivo and in vitro analyses, the limited number of neurons and glial cell types comprising the mature retina, and the high degree of conservation of many developmental signaling mechanisms ([@bib13]). The retinal cell types are derived in a temporal sequence from a common pool of multipotent progenitor cells ([@bib68]; [@bib7]). This conserved birth order is dependent on both intrinsic changes in competence of progenitor cells as well as cellular responses to environmental cues ([@bib62]; [@bib3]; [@bib72]; [@bib6]; [@bib32]).

The Sonic hedgehog (Shh) pathway is a highly conserved cell extrinsic regulator of progenitor cell proliferation and diversification in many tissues, including the developing CNS and neural retina ([@bib38]; [@bib9]). Patched (Ptch) is the transmembrane receptor for Shh and normally antagonizes the activity of the transmembrane protein Smoothened (Smo), which is required for the activation of the Gli zinc finger transcription factors. Shh binding to Ptch alleviates the Ptch-mediated repression of Smo, allowing activation of Gli transcription factors and expression of target genes ([@bib61]).

In the mouse retina, Shh is secreted from postmitotic retinal ganglion cells (RGCs) and targets retinal progenitor cells (RPCs; [@bib65]). Activation of the Shh pathway increases the proliferation of RPCs ([@bib29]; [@bib35]; [@bib5]; [@bib43]; [@bib44]; [@bib65]), whereas conditional inactivation of *Shh* results in decreased numbers of progenitor cells, confirming a role for Shh in RPC proliferation ([@bib65]). Genetic ablation of *Shh* in the embryonic mouse retina also results in increased RGC production, revealing a role for Shh signaling in cell fate regulation ([@bib65]). During later stages of retinal development, loss of Shh signaling results in a reduction of Müller glial cells and bipolar neurons, which is only restored with Shh pathway activation, indicating a potential instructive role for Shh in specifying cell fate ([@bib64]). Few Gli target genes important for these Shh-induced cellular responses have been identified. Cyclin D1, the major D-type cyclin expressed in the retina, is a reported target of Shh signaling during retinal development ([@bib65]; [@bib36]). However, loss of *Cyclin D1* in the retina does not recapitulate the cell fate changes observed with loss of Shh signaling ([@bib37]), which indicates that other unidentified targets of Shh/Gli signaling are necessary for establishing Shh-dependent effects.

Hes1 is a basic helix-loop-helix (bHLH) repressor and functions as a target of Notch signaling, a pathway that plays a key role in maintaining neural progenitor identity ([@bib31]). There are several redundant functions of Shh and Hes1 during CNS and retinal development that suggest convergence of these pathways. For example, Hes1 has been implicated in regulating cell cycling in the chick retina and Müller cell development in the mouse retina ([@bib16]; [@bib59]; [@bib19]). Also, the retinas of *Hes1* and *Shh* mutants are phenotypically similar, as both are characterized by an increased production of RGCs, precocious cell cycle exit, and depletion of RPCs ([@bib59]; [@bib65]). In contrast, conditional *Notch1* mouse mutants are characterized by a propensity to develop cone photoreceptors without an increase in RGC development ([@bib28]; [@bib67]). The differing phenotypes resulting from loss of *Notch* and *Hes1* in the retina suggest that Hes1 may have Notch-independent roles in retinal development. Furthermore, preliminary observations indicate that Shh signaling may influence the maintenance of *Hes1* expression in the retina ([@bib65]).

Here, we establish a novel, Shh-dependent regulatory mechanism for controlling neural progenitor cell behavior. Inhibition of Hes1 activity results in a decrease in RPC proliferation as well as a disruption of neuronal cell development in response to Shh pathway activation. Furthermore, the increased proliferation characterizing *PtchlacZ*^+/−^ retinas is rescued in compound *PtchlacZ*^+/−^*Hes1*^+/−^ heterozygous mice, which suggests that *Hes1* is epistatic to *Ptch* and is required to potentiate the proliferative response induced by the Shh pathway in vivo. We show that modulation of *Hes1* by Shh requires signaling through the activator Gli2 and is independent of the Notch pathway. Finally, chromatin immunoprecipitation (ChIP) analysis suggests that *Hes1* is a Shh-dependent, direct transcriptional target of Gli2. Thus, we have identified a novel mechanism linking Shh, Gli2, and Hes1 that is important for controlling neural progenitor cell proliferation.

Results
=======

Hes1 is activated by Shh signaling in a temporally regulated manner
-------------------------------------------------------------------

To investigate the Shh dependence of *Hes* gene expression in RPCs, we used retina organ cultures (explants) derived from postnatal mice ([Fig. 1 a](#fig1){ref-type="fig"}). Key features of normal retinal development, including critical cell fate decisions, are recapitulated in retinal cell explant cultures ([@bib71]). We have shown previously that Shh induction of target genes is abolished in postnatal mouse retinal explants due to the death of Shh-secreting RGCs because of a lack of trophic support from target tissues in the CNS ([@bib64]). We treated retinal explants with a Smo agonist ([@bib14]), which restores Hedgehog (Hh) target gene expression ([@bib65]), and analyzed *Hes* induction by quantitative RT-PCR (RT-qPCR). Activation of the Shh pathway in retinal explants derived from postnatal mice results in an ∼20-fold induction of *Hes1* mRNA ([Fig. 1 b](#fig1){ref-type="fig"}). Interestingly, Shh signaling in explants cultured from embryonic day 14 (E14) retinas resulted in only a twofold induction of *Hes1* mRNA, which indicates temporal regulation of the magnitude of *Hes1* expression by the Shh pathway. The modest induction of *Hes1* at E14 is not caused by a lack of progenitor cell competence to respond to Shh because the Hh target gene, *Gli1*, is potently activated by Shh in both E14 and postnatal retinal explants ([Fig. 1 b](#fig1){ref-type="fig"}). These data indicate that *Hes1* is inducible by Shh signaling at developmental stages when Shh is regulating both RGC development and RPC proliferation. A similar temporal regulatory pattern was observed for *Hes5* in response to Shh signaling. Shh activation resulted in a fivefold induction of *Hes5* mRNA in postnatal retinal explants, whereas no significant induction was observed in E14 explants ([Fig. 1 b](#fig1){ref-type="fig"}). Shh pathway activation also results in stabilization of Hes1 protein ([Fig. 1 c](#fig1){ref-type="fig"}), whereas Hes1 protein was undetectable in untreated explants devoid of Shh ligand, which indicates that an active Hh pathway is necessary for the maintenance of Hes1 in RPCs.

![**Shh is required to maintain Hes1 protein and mRNA in postnatal retinal explants.** (a) Diagram of the retinal explant culture method. Once the retina is surgically detached from the lens and surrounding ocular tissues, it is flattened by making four incisions and cultured on a membrane in the presence of a Smo agonist to activate the Hh signaling pathway. A cross section of a postnatal retinal explant is shown demonstrating *Gli1* transcript expression in the Hh-responsive progenitor cells of the neuroblast region. The RGC layer is comprised of a population of postmitotic neurons that are not responsive to Hh signaling. Bar, 100 μm. (b) Retinal explants were treated with and without a Smo agonist at E14 (*n* = 3) and P0 (*n* = 3) for 3 d in culture and analyzed for *Hes1*, *Hes5*, and *Gli1* mRNA by RT-qPCR. Values represent fold mRNA induction in Smo agonist--treated explants relative to untreated explants. Error bars represent SEM. \*, P \< 0.05. (c) Western blot for Hes1 from P0 retinal explants cultured for 3 d from untreated and Smo agonist--treated explants; β-tubulin protein level was used as a loading control.](jcb1840101f01){#fig1}

Shh activation of Hes1 and Hes5 does not require the active NICD
----------------------------------------------------------------

Notch is a transmembrane protein and requires cleavage by a γ-secretase complex to free its active intracellular domain (NICD) and induce target genes including *Hes1* and *Hes5* ([@bib30]). To address whether Shh induction of *Hes1* and *Hes5* requires Notch signaling, we used a widely used chemical inhibitor of the γ-secretase complex, *N*-\[*N*-(3,5-difluorophenacetyl)-[l]{.smallcaps}-alanyl\]-S-phenylglycine t-butyl ester (DAPT), to inhibit propagation of the Notch pathway ([@bib17]). *Hes5*, which is robustly expressed in untreated retinal explants, was used as a read-out for Notch signaling. *Hes5* was down-regulated in DAPT-treated retinal explants, which verifies Notch inactivation with DAPT treatment ([Fig. 2, m and o](#fig2){ref-type="fig"}) and is consistent with previous reports showing the Notch dependence of *Hes5* expression in RPCs ([@bib46]). Activation of the Hh pathway was accomplished using a constitutively active allele of Smo (Smo-M2; [@bib66]). Transfection of RPCs was accomplished using electroporation of transgenes in retinal explants. It has been previously found that transfection efficiency of postmitotic cells in electroporated retinal explants is very low, which indicates that dividing cells are the primary targets for electroporation ([@bib40]). Retinal explants were coelectroporated with Smo-M2 and pUb-GFP to localize the transfected cells, and simultaneously treated with DAPT for Notch pathway inactivation. In situ hybridization (ISH) for *Gli1* confirmed Shh pathway activation in response to Smo-M2 ([Fig. 2, f and h](#fig2){ref-type="fig"}). Induction of Shh signaling with SMO-M2 resulted in a cell-autonomous increase in *Hes1* and *Hes5* mRNA in the presence of DAPT, which indicates that Shh activation of these genes is independent of the NICD ([Fig. 2, l and p](#fig2){ref-type="fig"}). It is also noteworthy that control retinal explants electroporated with pUb-GFP, which do not exhibit Shh signaling, do not have detectable *Hes1* expression ([Fig. 2 i](#fig2){ref-type="fig"}). Because endogenous *Hes5* expression is lost with DAPT treatment, this suggests that Notch signaling is active in control retinal explants yet insufficient to maintain *Hes1* expression.

![**Shh activation of *Hes1* and *Hes5* is independent of Notch signaling.** Retinas at P0 were electroporated with SMO-M2 cotransfected with pUB-GFP or pUB-GFP alone and cultured for 3 d with DAPT or DMSO control. (a--d) GFP fluorescence localizes the transfected cells. ISH was performed for *Gli1* (e--h), *Hes1* (i--l), and *Hes5* (m--p). Differences in the localization of transfected cells within the explants are caused by folding and twisting during tissue processing. Bars, 100 μm. (q) Retinal explants (P0 + 3 days in vitro \[DIV\]) were electroporated with Smo-M2/pUb-GFP, treated with DAPT, dissociated, and scored for the proportion of BrdU+GFP+/GFP+ cells. The magnitude of Smo-M2--induced proliferation is not changed with DAPT treatment. Error bars represent SEM. \*, P \< 0.05; \*\*, P \< 0.005.](jcb1840101f02){#fig2}

We also tested whether Shh activation can induce cellular proliferation in RPCs independently of Notch signaling. Retinal explants were electroporated with SMO-M2, treated with DAPT, dissociated, and scored for BrdU incorporation. Antagonizing Notch activity did not significantly affect the proliferative effect of Shh signaling, which indicates that Shh can regulate progenitor cell behavior in a Notch-independent manner ([Fig. 2 q](#fig2){ref-type="fig"}).

Differential mechanism for the induction of Hes1 and Hes5 by Shh signaling
--------------------------------------------------------------------------

Although the previous experiment ([Fig. 2](#fig2){ref-type="fig"}) demonstrates that Shh can regulate *Hes1* independently of NICD activity, it does not address whether other downstream effectors of the Notch pathway are responsible for mediating Shh-dependent *Hes1* expression. We next asked whether the induction of *Hes1* by the Shh pathway requires the activity of RBPJ-κ by investigating *Hes1* induction in the context of RBPJ-κ knockdown. To control for the specificity of the shRBPJ-κ, we show that Notch (NICD; [@bib49])-mediated activation of a Notch reporter in retinal explants is abrogated by coexpression of shRBPJ-κ (Fig. S1, available at <http://www.jcb.org/cgi/content/full/jcb.200805155/DC1>). Retinal explants from postnatal day 0 (P0) mice were electroporated with an shRBPJ-κ plasmid and cotransfected with pUb-GFP to localize the transfected cohort of cells. *Gli1* is induced in the presence of the control and shRBPJ-κ vectors, which indicates activation of the Shh pathway (unpublished data). ISH analysis revealed a marked reduction in *RBPJ-κ* mRNA in transfected cells, which was also associated with a cell-autonomous reduction of *Hes5* mRNA, which provides additional confirmation of the specificity of the knockdown ([Fig. 3, f and l](#fig3){ref-type="fig"}). ISH for *Hes1* demonstrates that *Hes1* is induced in RPCs by the Smo agonist despite *RBPJ-κ* knockdown ([Fig. 3 i](#fig3){ref-type="fig"}). However, the Shh pathway is unable to induce *Hes5* in cells expressing the shRBPJ-κ construct ([Fig. 3 l](#fig3){ref-type="fig"}). This result infers a differential mechanism for the modulation of *Hes1* and *Hes5* by Shh signaling. The induction of *Hes1* via Shh is independent of the Notch signaling pathway, whereas induction of *Hes5* requires functional RBPJ-κ signaling.

![**RBPJ-κ signaling is not required for Shh induction of *Hes1* but is necessary for Shh induction of *Hes5*.** Retinal explants were electroporated with shRBPJ-κ or a control short hairpin plasmid at P0 and cultured for 4 d with or without a Smo agonist. (a--c) GFP fluorescence localizes the transfected cells. ISH was performed for *RBPJ-κ* (d--f), *Hes1* (g--i), and *Hes5* (j--l). Bar, 100 μm. (m) Retinal explants were coelectroporated with an empty vector control, NICD, or Smo-M2 and pUB-GFP, and cultured for 3 d, then *Hes1* expression was analyzed by RT-qPCR. Values represent the relative induction of *Hes1* expression normalized to GFP. Error bars represent SEM. \*, P \< 0.005.](jcb1840101f03){#fig3}

Activated Notch signaling is a weak regulator of Hes1 in RPCs
-------------------------------------------------------------

Because Shh-mediated induction of *Hes1* is independent of Notch signaling, we wanted to compare the efficiency of the Shh and Notch pathways in activating *Hes1* in RPCs. The active NICD, Smo-M2, or an empty-vector control were coelectroporated with pUB-GFP in retinal explant cultures. *Hes1* expression was analyzed using RT-qPCR and normalized to GFP to account for variations in transfection efficiency. Activation of the Hh pathway resulted in a 10-fold greater *Hes1* induction compared with Notch pathway activation ([Fig. 3 m](#fig3){ref-type="fig"}), which indicates that *Hes1* expression in RPCs is primarily responsive to the Shh pathway when compared with Notch signaling.

Shh induction of Hes1 requires signaling through activator Gli2
---------------------------------------------------------------

The major downstream activators of the Shh pathway are the Gli1 and Gli2 transcription factors, which activate target gene expression in response to Smo signaling ([@bib52]; [@bib1]). *Gli1* and *Gli2* are also expressed in the Hh-responsive neuroblast region of the developing retina. To evaluate the role of activator Gli function in the regulation of *Hes1*, we generated *Gli1^−/−^*, *Gli2^−/−^*, and *Gli1^−/−^Gli2^−/−^* mutant mice. Retinal explants derived from these mice were cultured in the presence of Smo agonist and analyzed by RT-qPCR for induction of *Hes1* mRNA. The Hh-mediated induction of *Hes1* was reduced fourfold in *Gli2^−/−^* explants compared with wild-type explants, whereas loss of Gli1 signaling did not effect *Hes1* induction ([Fig. 4 a](#fig4){ref-type="fig"}). These data indicate that Gli2 is the predominate factor responsible for *Hes1* regulation downstream of Shh activation. However, *Hes1* induction was completely attenuated in retinal explants cultured from *Gli1^−/−^Gli2^−/−^* compound mutant mice in response to Hh pathway activation, which indicates that Gli1 can minimally compensate for *Hes1* activation in the absence of Gli2 signaling ([Fig. 4 a](#fig4){ref-type="fig"}). To establish a link between Gli2 signaling and *Hes1* expression in vivo, we analyzed endogenous levels of *Hes1* in acutely dissected *Gli2^−/−^* and wild-type E18 retinas ([Fig. 4 b](#fig4){ref-type="fig"}). *Hes1* expression is down-regulated nearly threefold in *Gli2^−/−^* retinas compared with wild-type retinas, which establishes Gli2 as an important regulator of *Hes1* expression in vivo.

![**Shh induction of *Hes1* requires Gli2.** (a) Retinal explants were cultured from wild-type (Wt; *n* = 5), *Gli1^−/−^* (*n* = 3), *Gli2^−/−^* (*n* = 6), and *Gli2^−/−^Gli1^−/−^* (*n* = 3) mice with or without a Smo agonist at E18 for 3 d, then analyzed for *Hes1* expression by RT-qPCR. Values represent fold mRNA induction in Smo agonist--treated explants relative to untreated explants. (b) RT-qPCR on acutely dissected retinas from E18 wild-type (*n* = 5) and *Gli2^−/−^* (*n* = 5) animals. Values represent fold mRNA induction in *Gli2^−/−^* retinas compared with the wild type. The black lines in the Western blot indicate that intervening lanes have been spliced out. (c) Western blot analysis of protein lysates from Myc-Gli2--transfected or control COS cells blotted with an anti-Gli2 antibody. The β-tubulin protein level was used as a loading control. (d) Schematic of the 10-kb region of the *Hes1* promoter. The Gli2-binding sites are indicated with the mismatched nucleotides relative to the ideal Gli consensus sequence in small letters. ChIP reveals enrichment of Gli2 at sites −7,808 bp and −146 bp upstream of the transcription start site in the *Hes1* promoter in retinal explants treated with a Smo agonist. No enrichment of Gli2 was detected at these sites in untreated retinal explants. Association of Gli2 at a region of the *Hes1* promoter that does not contain a Gli consensus sequence was used as a negative control. (e) Western blot analysis for Gli2 on retinal explants treated with or without a Smo agonist (P0 + 3 DIV). The β-tubulin protein level was used as a loading control. (f and g) Retinal explants cultured with or without a Smo agonist for 3 DIV and subjected to ISH for *Gli2*. Bars, 100 μm. (h) Retinal explants (P0) were cultured with (*n* = 5) or without a Smo agonist (*n* = 4) for 6 h and analyzed for *Hes1* and *Gli1* expression by RT-qPCR. Values represent fold mRNA induction in Smo agonist--treated explants relative to untreated explants. Error bars represent SEM. \*, P \< 0.05; \*\*, P \< 0.001.](jcb1840101f04){#fig4}

Because the induction of *Hes1* by Shh does not require signaling through Notch but does require Gli2, we addressed whether *Hes1* is a direct transcriptional target of Gli2. To study Hes1 regulation in vitro, we generated a luciferase reporter containing the *Hes1* promoter and 10 kb of additional upstream sequence. The *Hes1* reporter is not sufficient to mimic endogenous *Hes1* activity by Hh signaling, which could indicate that we have not identified all of the relevant regulatory sequences or that the function of Gli2 in this context will not be revealed in simple reporter assays with nonchromatinized substrates ([@bib33]; [@bib48]). We therefore examined the possibility of Shh-mediated regulation of *Hes1* in the context of native chromatin by performing ChIP. These experiments allowed us to determine whether Gli2 binds the *Hes1* promoter in a physiologically relevant context. Candidate Gli consensus sequences were identified within a 10-kb region of the *Hes1* promoter and analyzed for association with Gli2 in control and Smo agonist--treated retinal explants. Validation of the specificity of the Gli2 antibody used for ChIP analysis was tested by Western blotting using COS cells transfected with a full-length *Gli2* expression plasmid or a GFP control plasmid ([Fig. 4 c](#fig4){ref-type="fig"}). Physical association of Gli2 at the *Hes1* promoter was detected at two putative Gli consensus sequences located at −146 bp and −7,808 bp upstream of the transcription start site ([Fig. 4 d](#fig4){ref-type="fig"}). Enrichment for Gli2 at the *Hes1* promoter was only detected in Smo agonist--treated explants, with no enrichment of Gli2 detected in untreated explants, which suggested that *Hes1* is a Shh-dependent direct transcriptional target of Gli2 ([Fig. 4 d](#fig4){ref-type="fig"}).

The observation that Gli2 binds the *Hes1* promoter only in the presence of Shh signaling may be attributed to the stability of Gli protein ([@bib24]; [@bib51]). To test this hypothesis, we investigated whether we can detect endogenous Gli2 protein in RPCs in the absence of Hh signaling. Western blot analysis revealed that Gli2 protein is only detected in cultures with an active Hh pathway despite the presence of Gli2 transcript in untreated retinal explants ([Fig. 4, e--g](#fig4){ref-type="fig"}). This data indicates that Hh signaling is necessary for the stability of Gli2 protein in RPCs and accounts for the Hh-dependent binding of Gli2 to the *Hes1* promoter.

To further explore the relationship between Shh signaling and *Hes1* regulation, we examined the kinetics of *Hes1* induction in retinal explants. Retinal explants treated with a Smo agonist for 6 h exhibited a significant induction of *Hes1* compared with untreated explants, strengthening the evidence of a direct relationship between *Hes1* and Hh signaling ([Fig. 4 h](#fig4){ref-type="fig"}). This induction of *Hes1* is not caused by decay of Hh signaling in untreated explants because retinal explants cultured for 6 h do not exhibit a significant decrease in levels of *Gli1* or *Hes1* when compared with acutely dissected retinas (Fig. S2, available at <http://www.jcb.org/cgi/content/full/jcb.200805155/DC1>).

Hes1 is necessary for Shh-mediated proliferation and cell fate specification in RPCs
------------------------------------------------------------------------------------

Because we have demonstrated a novel mechanism for *Hes1* regulation by Shh-Gli2 signaling, we wanted to examine the physiological significance of *Hes1* as a Shh target gene. To investigate this, we used *PtchlacZ^+/−^* mice, which exhibit constitutive Hh pathway activation that results in delayed cell cycle exit in the central retina of postnatal mice ([@bib5]; [@bib43]). To directly evaluate whether *Hes1* is necessary for the Hh-mediated proliferation of progenitor cells in vivo, we generated *PtchlacZ^+/−^Hes1^+/−^* compound heterozygous mice. We chose to work with mice heterozygous for *Ptch* because *Ptch^−/−^* mutants exhibit early embryonic lethality before retinal development ([@bib18]). Immunohistochemistry (IHC) for the mitotic marker pH3 revealed that mitotic cells were reduced in the compound heterozygous retinas (*PtchlacZ^+/−^Hes1^+/−^*) compared with retinas from *PtchlacZ^+/−^* mice ([Fig. 5, a--c](#fig5){ref-type="fig"}). Furthermore, quantification of BrdU incorporation from retinal sections of *PtchlacZ^+/−^Hes1^+/−^* double heterozygous animals revealed a significant reduction in the total number of cells in S phase compared with *PtchlacZ*^+/−^ retinas, which demonstrates that Hes1 is a mediator of Shh-dependent proliferation in the retina in vivo ([Fig. 5 d](#fig5){ref-type="fig"}). Also, quantification of the proportion of BrdU-labeled cells from dissociated retinas revealed a significant increase in proliferation in *PtchlacZ*^+/−^ retinas compared with the wild type; however, there was no significant increase in proliferation in *PtchlacZ^+/−^Hes1^+/−^* retinas ([Fig. 5 e](#fig5){ref-type="fig"}). This data provides novel evidence for an in vivo genetic interaction between Hh signaling and *Hes1* in the regulation of progenitor cell proliferation.

![**Shh-mediated RPC proliferation and cell fate specification requires *Hes1*.** (a--c) In vivo anti-pH3 staining of the central retina adjacent to the optic nerve (asterisks) in P5 wild-type (Wt), *PtchlacZ^+/−^*, and *PtchlacZ^+/−^Hes1^+/−^* retinas. Arrows indicate pH3-positive cells. Note that pH3+ cells in the vicinity of the optic nerve are rare in Wt and compound heterozygous mice. Bar, 100 μm. (d) Quantitative analysis of BrdU incorporation in vivo from P5 Wt (*n* = 3), *Hes1^+/−^* (*n* = 3), *PtchlacZ^+/−^* (*n* = 3), and *PtchlacZ^+/−^Hes1^+/−^* (*n* = 6) retinas. Values represent the mean number of BrdU-positive cells counted from three sections per animal. (e) Quantification of the proportion of BrdU^+^ cells in single-cell dissociates from the retinas of Wt (*n* = 5), *Hes1^+/−^* (*n* = 3), *PtchlacZ^+/−^* (*n* = 8), and *PtchlacZ^+/−^Hes1^+/−^* (*n* = 7) retinas at P5. (f) Retinal explants from *Hes1^−/−^* (*n* = 3) or Wt (*n* = 3) animals were treated with a Smo agonist for 3 d, dissociated, and scored for the proportion of BrdU^+^DAPI^+^ cells. (g) Quantitative analysis for BrdU, CRALBP, Chx10, rhodopsin, and recoverin-positive cells in Smo agonist--treated P0 retinal explants electroporated with GFP and Hes1DN. Values are based on scoring marker+ cells among the transfected cohort in dissociates from retinal explants and represent the fold induction of double-positive (marker+GFP+) cells in GFP + Ag and Hes1DN + Ag cultures compared with double-positive cells in GFP-transfected untreated explants. There is no difference in proliferation or cell type composition in GFP and Hes1DN-transfected cells in untreated explants. Error bars represent SEM. \*, P \< 0.05; \*\*, P \< 0.01.](jcb1840101f05){#fig5}

We also investigated the proliferative response induced by Shh in *Hes1^−/−^* mutant retinal explants. Loss of *Hes1* resulted in a significant decrease in Shh-mediated BrdU incorporation compared with wild-type explants ([Fig. 5 f](#fig5){ref-type="fig"}). To study whether acute inhibition of Hes1 activity antagonizes progenitor cell proliferation in response to Shh, we antagonized Hes1 activity using a previously characterized Hes1DN construct that carries three point mutations in the basic DNA-binding domain that interfere with its DNA-binding activity ([@bib58]). The Hes1DN protein will dimerize with wild-type Hes1 and HesR proteins to form transcriptionally inactive complexes. Retinal explants were electroporated with the Hes1DN construct and cultured in the presence of a Smo agonist for 3 d in vitro. The explants were dissociated by enzymatic digestion followed by IHC for cell type--specific markers and scored for marker+ cells among the transfected cohort of cells, which was identified by GFP fluorescence. Normally, Smo agonist treatment of control electroporated RPCs results in an increased proportion of dividing progenitors compared with control explants (Fig. S3, available at <http://www.jcb.org/cgi/content/full/jcb.200805155/DC1>). BrdU incorporation in response to the agonist was reduced by 50% in the Hes1DN-expressing cohort compared with the GFP-expressing cells ([Fig. 5 g](#fig5){ref-type="fig"}), which indicates that Hes1 is required for Shh-mediated proliferation. This data also reinforces the hypothesis that Hes1 is a Notch-independent target of Shh, as inhibition of Notch signaling did not compromise Shh-induced proliferation ([Fig. 2 q](#fig2){ref-type="fig"}).

The Shh pathway also promotes the development of Müller glia and bipolar cells at the expense of rod photoreceptors (Fig. S3; [@bib65]; [@bib69]). As Hes1 has been implicated as a regulatory factor in promoting bipolar and Müller cell specification ([@bib60]; [@bib16]; [@bib59]), we investigated whether Hes1 was required for the acquisition of specific cell fates downstream of Shh signaling. Retinal explants were electroporated with the Hes1DN construct or GFP, cultured with the Smo agonist for 7 d in vitro, and dissociated and scored using IHC for specific cell type markers. Significantly, there was a 50% reduction in the proportion of Müller (anti-cellular retinaldehyde-binding protein \[CRALBP\]) and bipolar cells (anti--Chx10) in agonist-treated Hes1DN-expressing cells compared with agonist-treated GFP-expressing cells ([Fig. 5 g](#fig5){ref-type="fig"}). The reduction in cells with a bipolar and Müller cell identity in the Hes1DN cohort was associated with an increase in the proportion of cells positive for rod photoreceptor markers rhodopsin and recoverin. Therefore, the Müller- and bipolar-promoting effects of Shh require Hes1.

Loss of Gli2 represses proliferation and cell fate specification in response to Shh signaling, similar to inhibition of Hes1
----------------------------------------------------------------------------------------------------------------------------

Because Gli2 is necessary for the induction of Hes1 by Shh signaling, we asked whether loss of Gli2 phenocopies the effect of Hes1 inhibition in the context of an activated Shh pathway. *Gli2^−/−^* mutant explants at E18 were cultured with the Smo agonist and analyzed for proliferation and the development of specific cell types. Proliferation was attenuated in *Gli2^−/−^*-treated explants relative to wild type--treated explants after 3 d ([Fig. 6](#fig6){ref-type="fig"}). Müller and bipolar cell development was also reduced in *Gli2^−/−^*-treated explants cultured for 7 d compared with control explants ([Fig. 6](#fig6){ref-type="fig"}), which demonstrates that Gli2 is required for Shh effects on cell type development. In contrast, Hh-mediated proliferation was normal in the absence of *Gli1* correlating with normal *Hes1* induction (unpublished data).

![**Gli2 is required for the Shh effects on proliferation and cell fate.** Retinal explants were cultured from wild-type (Wt; *n* = 3) and *Gli2^−/−^* (*n* = 3) mice at E18 for 3 d in culture with or without a Smo agonist. IHC was performed on dissociated cells using anti-BrdU, anti-CRALBP, anti-rhodopsin, and anti-recoverin antibodies. Values represent the fold induction of positive cells in Wt + Ag or *Gli2^−/−^* + Ag cultures compared with nontreated explants. Error bars represent SEM. \*, P \< 0.05; \*\*, P \< 0.01.](jcb1840101f06){#fig6}

Discussion
==========

In this study, we sought to identify the molecular mechanisms that Shh utilizes to regulate CNS progenitor cell behavior. We have used the neural retina as a model for CNS development to evaluate the mechanism and function of *Hes1* as a putative Shh target gene. *Hes1* is a key target of the Notch pathway, and its role during development is normally associated with activated Notch signaling. However, *Hes1* mutant retinas do not mimic *Notch1* mutants, which suggests that Hes1 may have Notch-independent roles in retinal development ([@bib59]; [@bib28]; [@bib67]). This idea is corroborated by the persistent expression of *Hes1* in *Notch1* and *RBPJ-κ* mutant embryos and the identification of other factors capable of activating *Hes1* ([@bib12]; [@bib16]; [@bib57]; [@bib47]; [@bib26]; [@bib45]). Also, inhibition of the Notch pathway in chick retinal explants results in a weak reduction of *Hes1* expression and a much more potent reduction in *Hes5* levels, which is further evidence for Notch-independent *Hes1* regulation ([@bib46]). Shh treatment of cerebellar granule precursors results in induction of *Hes1*, which suggests a more general role for Shh in the regulation of *Hes1* in CNS development ([@bib56]). Here, we show that Gli2 is a novel regulator of *Hes1* expression and that Hes1 is a novel mediator of Shh-mediated proliferation in neural progenitors. Surprisingly, we have observed a differential mechanism for Shh-mediated regulation of *Hes1* and *Hes5*. Induction of *Hes5* is independent of Notch; however, it requires signaling by RBPJ-κ, suggesting that RBPJ-κ can function independently of Notch downstream of Shh activation. To date, Notch-independent RBPJ-κ activity has only been reported in *Drosophila melanogaster* mechanoreceptor physiology, mouse pancreas development, and the specification of GABAergic neurons ([@bib2]; [@bib4]; [@bib22]).

The requirement for both Shh- and Notch-driven regulation of *Hes1* in progenitor cells may be explained by several hypotheses. First, Shh and Notch could be targeting different progenitor populations. A recent study has shown that the activated NICD is heterogeneously expressed in subsets of progenitors in the mouse retina ([@bib46]), which implies that not all progenitors are responsive to activated Notch signaling. Second, progenitor cells are sensitive to Hes1 dosage; therefore, Notch and Shh signaling may be required to achieve the spectrum of Hes1 levels needed for cell fate specification and proliferation. For example, *Hes1^+/−^* retinas exhibit accelerated rod photoreceptor differentiation without the proliferative or RGC phenotype characterizing *Hes1^−/−^* retinas ([@bib59]). Also, the decision to adopt an RGC fate is dependent on levels of proneuronal bHLHs NGN2 and Math5 as well as Hes1, with high levels of Hes1 antagonizing Math5 expression and function and thereby inhibiting the RGC fate ([@bib41]). Mechanistically, oscillation in Hes1 expression ([@bib21]) could be one way to achieve functionally relevant modulations in Hes1 levels in progenitor cells. Notch-induced Hes1 oscillation is required for the maintenance of neural progenitors ([@bib55]), and it is conceivable that the effects of Hh signaling on Hes1 expression could be mediated by a similar mechanism. Further analysis is necessary to determine the mode of Hes1 expression in the context of Hh pathway activation.

We have identified a direct interaction of Gli2 and *Hes1* at two Gli consensus sites in the *Hes1* promoter. In these studies, we obtained strong evidence for a direct effect because ChIP analysis using primary RPCs revealed Shh-dependent recruitment of Gli2 to the *Hes1* promoter in vivo. These findings, coupled with our strong genetic evidence linking Shh to *Hes1*, provide the first example of an interaction between Gli2 signaling and *Hes1* expression, and the first example of the importance of this mechanism in the regulation of progenitor cell proliferation. Our findings also raise the possibility that Gli2-dependent regulation of proliferation in other tissues could function with a similar mechanism ([@bib39]; [@bib8]; [@bib50]; [@bib25]; [@bib23]; [@bib70]). In addition to activator Gli1 and Gli2 function, the Gli3 transcription factor is also a mediator of the Shh pathway, and it functions to repress target genes in the absence of Shh signaling. Because loss of function of both Gli1 and Gli2 completely attenuates Shh-mediated induction of *Hes1*, it appears that derepression of Gli3 is not a primary regulator in this context.

Hh control of *Hes1* appears to be an evolutionary conserved signaling mechanism involved in widespread tissue patterning. Hh drives expression of the *D. melanogaster* homologue of *Hes1*, *hairy*, along the dorsal/ventral axis of the leg imaginal disc to negatively regulate the development of sensory cell fates ([@bib20]). The induction of *hairy* in response to Hh requires Cubitus interruptus (Ci), the *D. melanogaster* homologue of Gli, and dorsal/ventral expression of *hairy* is lost in Smo-deficient clones ([@bib20]). Patterning of the retinal field during development of the *D. melanogaster* compound eye also reveals Notch-independent regulation of hairy by Hh ([@bib15]). In this system, both Hh and Notch negatively regulate *hairy* expression to promote a wave of photoreceptor differentiation.

In this study, we have elucidated a novel mechanism for Shh-controlled progenitor cell behavior. Our observation that Gli2 occupies the *Hes1* promoter is one of the first identified direct relationships between Gli2 and a target gene in neural progenitor cells. This study provides a mechanistic link between Shh-Gli2 signaling and Hes1 in regulating the proliferation of RPCs, thereby shedding light on a new means of manipulating Shh-induced cellular responses.

Materials and methods
=====================

Transgenic mice
---------------

Several transgenic mouse lines were used in this study. *PtchlacZ^+/−^* mice ([@bib18]) were obtained from the Jackson Laboratory and maintained on a C57Bl6 background; *Gli1^+/−^* and *Gli2^+/−^* mice (obtained from A. Joyner, Sloan-Kettering Institute, New York, NY; [@bib42]; [@bib52]), and *Hes1^+/−^* ([@bib27]) were maintained on a CD1 background. *PtchlacZ^+/−^*were crossed with *Hes1^+/−^* mice to generate double heterozygous mice (*PtchlacZ^+/−^Hes1^+/−^*). *Gli1^+/−^* and *Gli2^+/−^* strains were mated to generate double heterozygous animals, *Gli1^+/−^Gli2^+/−^*, which were subsequently crossed to give double homozygous null mice *Gli1^−/−^Gli2^−/−^*. Unless otherwise stated, retinal explants were derived from CD1 (the Jackson Laboratory) wild-type mice.

Cell culture, retinal explants, and BrdU labeling
-------------------------------------------------

Mouse strains were continuously mated or time-mated to generate specimens of the appropriate age, with the day of the vaginal plug designated day 0 of gestation. Retinal explants were prepared as described previously ([@bib65]). Retinal explant medium was supplemented with 10 nM of Smo agonist (Ag1.10; a kind gift from Curis, Inc.; [@bib14]) or 10 μM DAPT (Millipore), then cultured at 8% CO~2~ and 37°C. Selected explants were labeled with 10 μM BrdU for the last 6 h of culture to identify cells in S phase. Explants were either fixed in a 4% paraformaldehyde phosphate buffer for 1 h, transferred to a 30% sucrose/PBS solution overnight, and embedded in 1:1 optimal cutting temperature/30% sucrose/PBS mixture or dissociated into single cells with trypsin (Sigma-Aldrich) and plated onto Superfrost slides (Sigma-Aldrich) for quantitative analysis as described previously ([@bib65]). COS cells were cultured in 10% FBS DME and transfected with full-length Myc-tagged Gli2 (a gift from H. Sasaki, RIKEN Center for Developmental Biology, Chuo-ku, Kobe, Japan; [@bib54]) or pUb-GFP (a gift from T. Matsuda, Harvard Medical School, Boston, MA) using Lipofectamine 2000 (Invitrogen) according to the manufacturer\'s instructions.

Histology, IHC, and ISH
-----------------------

IHC or ISH was performed as described previously ([@bib29]; [@bib63]; [@bib10]). Antibodies used in this study include rabbit polyclonal anti-CRALBP (a kind gift from J. Saari, University of Washington, Seattle, WA), mouse monoclonal anti-BrdU (BD), mouse monoclonal anti-rhodopsin ([@bib53]), rabbit polyclonal anti-recoverin (Millipore), sheep polyclonal anti-Chx10 (a gift from R. Bremner, Toronto Western Research Institute, Toronto, Ontario, Canada), rabbit polyclonal phosphohistone H3 (Millipore), and rabbit polyclonal anti-GFP (Invitrogen). Secondary antibodies include donkey anti--goat IgG Cy3 (Invitrogen), goat anti--rabbit IgG FITC (Invitrogen), goat anti--mouse IgG Cy3 (Jackson ImmunoResearch Laboratories), and goat anti--rabbit IgG Cy3 (Jackson ImmunoResearch Laboratories). The antisense riboprobes used for ISH include Gli1 (a gift from A. Joyner), RBPJ-κ (a gift from T. Hongo, Kyoto University, Kyoto, Japan), Gli2 (a gift from H. Sasaki), Hes1, and Hes5. Bright field images were analyzed using an Axioplan microscope and captured with an Axiovision camera (2.05; both from Carl Zeiss, Inc.). Pictures were taken at magnifications of 10× (NA 0.30) and 20× (NA 0.05; both from Carl Zeiss, Inc.). Fluorescent images were analyzed using an Axiocam microscope (HRm) and captured with an Axioimager camera (M1; both from Carl Zeiss, Inc.). Florescent images were taken at 20× (0.8 NA). All images were processed using Photoshop CS2 (Adobe).

In vitro electroporation
------------------------

Electroporation was performed on retinal explants based on the protocol from [@bib40]. Explanted retinas were electroporated (ECM 830; BTX Harvard Apparatus) in a 2-mm gap cuvette (VWR) with 0.5--1.5 μg/μl of plasmid DNA in endotoxin-free TE buffer with a 10:1 ratio of plasmid DNA/pUb-GFP or pUb-GFP alone. The DNA plasmids used in this study include: SMO-M2 (a gift from G. Fishell, New York University Langone Medical Center, New York, NY), an activated NICD (a gift from G. Weinmaster, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA), LacZ 2.1 double-stranded shcontrol (Invitrogen), shRBPJ-k (Invitrogen), and Hes1DN.

Western blotting
----------------

Protein was extracted from Smo agonist--treated and nontreated retinal explant cultures using RIPA buffer (125 mM Tris-HCL, 2% SDS + protease inhibitor cocktail), and Western blotting performed as described previously ([@bib11]). Protein samples were probed with 1:1,500 rabbit polyclonal anti-Hes1 (a gift from N. Brown, University of Cincinnati College of Medicine, Cincinnati, OH), 1:200 dilution of goat polyclonal anti-Gli2 (sc-20291; Santa Cruz Biotechnology, Inc.), 1:500 dilution of rabbit polyclonal Gli2 (Abcam), or 1:50 dilution of mouse monoclonal antibody E7 ascites (Developmental Studies Hybridoma Bank). Secondary antibodies used include goat anti--rabbit IgG HRP (1:5,000; Sigma-Aldrich), donkey anti--goat HRP (1:3,000; Santa Cruz Biotechnology, Inc.), and sheep anti--mouse IgG HRP (1:3,000; Sigma-Aldrich).

RT-qPCR
-------

RNA was harvested from Smo agonist--treated and nontreated retinal explants using Trizol (1 explant per 1 ml of Trizol). cDNA was synthesized using 2 μg of total RNA with the Invitrogen kit according to the manufacturer\'s instructions. qPCR was performed using 1 μl of cDNA with Brillant SyBr Green mastermix (Agilent Technologies) according to the manufacturer\'s instructions, with the exception that the reaction was scaled down to a total volume of 25 μl. Primers (200 nM) used include Hes1 (forward, 5′-AAAGACGGCCTCTGAGCACA-3′; reverse, 5′-TCATGGCGTTGATCTGGGTCA-3′), Hes5 (forward, 5′-AAGAGCCTGCACCAGGACTA-3′; reverse, 5′-CGCTGGAAGTGGTAAAGCA-3′), and 18S (forward, 5′-CGGCTACCACATCCAAGG-3′; reverse, 5′-CTGGAATTACCGCGGCT-3′), and GFP (forward, 5′-CGTCGCCGTCCAGCTCGACCAG-3′; reverse, 5′-CATGGTCCTGCTGGAGTTCGTG-3′), Gli1 (forward, 5′-CACTACCTGGCCTCACACCT-3′; reverse, 5′-GTACTCGGTTCGGCTTCTCC-3′). The PCR reaction was performed on a MX3000P (Stratagene) with 40 amplification cycles. Changes in gene expression were quantified based on the 2^ΔCt^ value normalized to 18S. Normalization to GFP was used to standardize for transfection efficiency in electroporated retinal explants. Statistical significance was determined using a two-tailed student\'s *t* test.

ChIP
----

Candidate Gli consensus sequences were identified as GACCACCCA or TGGGTGGTC ([@bib34]), and primers were designed to amplify regions of genomic DNA that contain at least a seven-base match within a 10-kb region of the Hes1 promoter. CD1 retinal explants treated with or without a Smo agonist for 3 d were fixed in cold 4% paraformaldehyde PBS solution (two explants per condition) for 30 min. The DNA was sheared to less than 1 kb by sonication. ChIP was performed using the EZ ChIP kit (Millipore) according to the manufacturer\'s instructions. Immunoprecipitations were performed using 10 μl of a goat anti-Gli2 polyclonal antibody (Santa Cruz Biotechnology, Inc.) or an irrelevant antibody of the same species (goat anti-Brn3b). DNA was analyzed using qPCR with 2 μl of DNA with Brilliant SyBr green mastermix (Stratagene) and 200 nM of Hes1 primers (−7,808 bp site: forward, 5′-CAGTGCTACAGACCACACAGG-3′; and reverse, 5′-AGAACGTGACATCGGCTTTC-3′; −146 bp site: forward, 5′-TCCTTTTGATTGACGTTGTAGC-3′; and reverse, 5′-CCCAAACTTTCTTTCCCACA-3′), with an annealing temperature of 60°C on a MX3000P for 40 cycles. A primer set (forward, 5′-TTGAGGGTTTTTGTTTTGTTTTG-3′; reverse, 5′-CGGTTGCTTTTTAAACAGTGG-3′) spanning a region of the Hes1 promoter without a Gli consensus sequence was used as a negative control. The Ct values were expressed relative to unprecipitated input chromatin and fold enrichment were calculated by 2^ΔCt^, where ΔCt = Ct (anti-Gli2 -- anti-control Brn3b). Standard deviation was calculated based on three independent experiments, and significance was calculated using a two-tailed student\'s *t* test.

Online supplemental material
----------------------------

Fig. S1 shows knockdown of Hes1 reporter activity in response to shRBPJ-κ. Fig. S2 confirms that *Hes1* and *Gli1* levels are maintained in retinal explant cultures after a culture period of 6 h. Fig. S3 shows the proportions of retinal cell types in response to Smo Ag treatment. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200805155/DC1>.
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